Skip to main content
    Paid monthly and annual subscribers can read every Medi-Chi book online — including clinical references and the TCM Textbook · downloads sold separatelySee the libraryClinical Education Tool — This platform provides educational resources for TCM practitioners and students. It does not issue medical certificates, prescriptions, or clinical diagnoses.
    respiratory

    Lung cancer

    Also known as: Pulmonary malignancy, Bronchogenic carcinoma, Non-small cell lung cancer, Small cell lung cancer

    Lung cancer comprises a heterogeneous group of malignancies necessitating formal histological confirmation, staging, and a multidisciplinary oncology strategy. Primary interventions include surgical resection, radiotherapy, or systemic therapies determined by histopathology and performance status. Complementary Chinese medicine serves strictly as supportive care to assist in managing symptoms such as lethargy, anorexia, or sleep disturbance. Current literature includes a retrospective cohort study indicating an association between acupuncture and a lower incidence of new-onset insomnia; however, this does not establish causality or a definitive treatment protocol. Current evidence does not support the efficacy of TCM patterns or formulas for oncological management; acupuncture and herbal medicine must not be promoted as methods to achieve local control, prevent metastasis, or prolong survival.

    Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.

    All clinical details on this page are for practitioner premium subscribers only.
    Checking your practitioner access
    Verifying your Medi-Chi access…

    Lifestyle & Diet

    • •Access professional smoking cessation services and minimise environmental exposure to particulate matter, passive smoke, and other respiratory irritants.
    • •Maintain a consistent circadian rhythm and report persistent insomnia to the multidisciplinary team; observational data does not support a mandated frequency for acupuncture intervention.
    • •Undertake gentle, individualised physical activity balanced with adequate rest; patients with bone metastases, breathlessness, or falls risk should consult a rehabilitation specialist. Research regarding the biology of brain metastases does not indicate that exercise serves as a preventative measure.
    • •Monitor body mass and nutritional intake closely; early consultation with an oncology dietitian is recommended. Patients should avoid restrictive dietary regimens or unverified supplementation.

    Cautions & Contraindications

    See sources
    • •Do not delay staging, oncology treatment or urgent assessment in favour of acupuncture or herbs. The older-adult small-cell cohort supports the importance of systemic oncology care but does not establish any herbal substitute.[]
    • •Defer needling with fever, suspected infection, uncontrolled bleeding or clinically significant treatment-related cytopenias until the oncology team has assessed safety. The supplied abstracts do not define safe blood-count thresholds; use local oncology protocols.[]
    • •Avoid needling through tumour deposits, infected or broken skin, recently operated or irradiated tissue, and around vascular access devices. Thoracic needling carries pneumothorax risk. These are clinical procedural precautions, not safety findings established by source 4.[]
    • •Do not initiate herbs during chemotherapy, immunotherapy, targeted therapy or perioperative care without full medication reconciliation and oncology-pharmacist review. The supplied review does not establish interaction safety for any listed formula; avoid herbs with unexplained liver injury pending assessment.[]
    • •The insomnia cohort does not establish safety for every patient or justify daily acupuncture or a minimum course of 16 sessions. Individualise treatment according to clinical stability, burden, preferences and oncology advice.[]

    When to reassess or seek care again

    See sources

    Establish baseline sleep disturbance, fatigue, pain and nausea scores on consistent 0–10 scales, together with weight, oral intake and rescue-medicine use. Review tolerability after every visit and overall benefit after 2–4 weeks of an agreed trial. Continue only when meaningful patient-valued benefit outweighs burden and risk. Refer promptly for worsening symptoms, falling intake or weight, increased analgesic requirements or suspected treatment toxicity; stop and escalate immediately for red flags. Review current blood counts and oncology restrictions when clinically indicated. No treatment schedule or response threshold is validated by the supplied abstracts.

    Explore more diseases

    Sources & Further Reading

    Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.

    1. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    2. Future oncology (London, England) · 2026
    3. Clinical & experimental metastasis · 2026
    4. Pain research & management · 2026

    Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.